

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 April 2004 (22.04.2004)

PCT

(10) International Publication Number
WO 2004/032923 A1

(51) International Patent Classification⁷: **A61K 31/427,**
A61P 35/00

Douglas [US/US]; 156 Dean Road, Brookline, MA 02445 (US).

(21) International Application Number:
PCT/IB2003/004480

(74) Agents: **DOHMANN, George, R.** et al.; Novartis, Corporate Intellectual Property, One Health Plaza Bldg. 430/2, East Hanover, NJ 07936-1080 (US).

(22) International Filing Date: 10 October 2003 (10.10.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/417,916 11 October 2002 (11.10.2002) US

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(71) Applicant (*for all designated States except US*): **DANA-FARBER CANCER INSTITUTE INC** [US/US]; 44 Binney Street, Boston; MA 02115 (US).

Published:

— with international search report


(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **LIN, Boris** [US/US]; 1032 North New Jersey Street, Indianapolis, IN 46202 (US). **ANDERSON, Kenneth, C.** [US/US]; 264 Weston Road, Wellesley, MA 02482 (US). **GRIFFIN, James,**

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/032923 A1

(54) Title: **EPOTHILONE DERIVATIVES FOR THE TREATMENT OF MULTIPLE MYELOMA**



(I)

(57) Abstract: The present invention relates to a method of treating a warm-blooded animal, especially a human, having myeloma, especially myeloma which is resistant to conventional cytotoxic chemotherapy, comprising administering to said animal a therapeutically effective amount of an epothilone, especially an epothilone of formula (I), to a combination comprising an epothilone, for simultaneous, separate or sequential use; and to a pharmaceutical composition and a commercial package comprising said combination.

BEST AVAILABLE COPY


EPOTHILONE DERIVATIVES FOR THE TREATMENT OF MULTIPLE MYELOMA

The present invention relates to a method of treating a warm-blooded animal, especially a human, having myeloma, especially myeloma which is resistant to conventional cytotoxic chemotherapy, comprising administering to said animal a therapeutically effective amount of an epothilone, especially an epothilone of formula I as defined herein; to a combination comprising an epothilone and a compound selected from the group consisting of alkylating agents, corticosteroids and anthracyclines, and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential use; and to a pharmaceutical composition and a commercial package comprising said combination.

The taxanes, such as paclitaxel and docetaxel, represent a class of microtubule stabilizing agents that is commonly used in a number of proliferative diseases, e.g., solid tumor diseases like ovarian cancer. However, the taxanes have not shown great promise in the treatment of myeloma. The epothilones, e.g., epothilones A, B and D, but also analogues thereof, represent a new class of microtubule stabilizing agents (see Gerth, K. et al., J. Antibiot. 49, 560-3 (1996); or Hoeffle et al., DE 41 38 042). Surprisingly, it was now found that epothilones, especially the epothilones of formula I as defined herein and, in particular, epothilone B, directly inhibit the growth and survival of myeloma cells.

Furthermore, adherence of patient multiple myeloma cells to bone marrow stromal cells (BMSCs), enhances the ability of epothilones to inhibit multiple myeloma cell proliferation and to promote cell death proliferation of myeloma cells that are adherent to BMSCs.

Hence, the invention relates to a method of treating myeloma, especially myeloma which is resistant to conventional cytotoxic chemotherapy, comprising administering a therapeutically effective amount of an epothilone, preferably a therapeutically effective amount of an epothilone of formula I



wherein A represents O or NR_N , wherein R_N is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino or methylthio, and Z is O or a bond,
or a pharmaceutically acceptable salt thereof to a warm-blooded animal, preferably a human, in need thereof.

The present invention pertains in particular to a method of treating myeloma wherein
(a) overexpression of the multi-drug resistance protein p170 is observed, and/or
(b) the myeloma is resistant to a taxane, e.g., paclitaxel or docetaxel.

The term "myeloma" as used herein relates to a tumor composed of cells of the type normally found in the bone marrow. The term "multiple myeloma" as used herein means a disseminated malignant neoplasm of plasma cells which is characterized by multiple bone marrow tumor foci and secretion of an M component (a monoclonal immunoglobulin fragment), associated with widespread osteolytic lesions resulting in bone pain, pathologic fractures, hypercalcaemia and normochromic normocytic anaemia. Multiple myeloma is incurable by the use of conventional cytotoxic and high dose chemotherapies.

Throughout the present specification and claims myeloma means preferably multiple myeloma (MM).

Unless stated otherwise, in the present disclosure organic radicals and compounds designated "lower" contain not more than 7, preferably not more than 4, carbon atoms.

A compound of formula I wherein A represents O, R is hydrogen, R' is methyl and Z is O is known as epothilone A; a compound of formula I wherein A represents O, R is methyl, R' is methyl and Z is O is known as epothilone B; a compound of formula I wherein A represents

O, R is hydrogen, R' is methyl and Z is a bond is known as epothilone C; a compound of formula I wherein A represents O, R is methyl, R' is methyl and Z is a bond is known as epothilone D.

Epothilone derivatives of formula I wherein A represents O or NR_N , wherein R_N is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl and Z is O or a bond, and methods for the preparation of such epothilone derivatives are in particular generically and specifically disclosed in the patents and patent applications WO 93/10121, US 6,194,181, WO 98/25929, WO 98/08849, WO 99/43653, WO 98/22461 and WO 00/31247 in each case in particular in the compound claims and the final products of the working examples, the subject-matter of the final products, the pharmaceutical preparations and the claims is hereby incorporated into the present application by reference to this publications. Comprised are likewise the corresponding stereoisomers as well as the corresponding crystal modifications, e.g. solvates and polymorphs, which are disclosed therein. Epothilone derivatives of formula I, especially epothilone B, can be administered as part of pharmaceutical compositions which are disclosed in WO 99/39694.

Epothilone derivatives of formula I wherein A represents O or NR_N , wherein R_N is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methoxy, ethoxy, amino, methylamino, dimethylamino or methylthio, and Z is O or a bond, and methods for the preparation and administration of such epothilone derivatives are in particular generically and specifically disclosed in the patent application WO99/67252, which is hereby incorporated by reference into the present application. Comprised are likewise the corresponding stereoisomers as well as the corresponding crystal modifications, e.g. solvates and polymorphs, which are disclosed therein.

The transformation of epothilone B to the corresponding lactam is disclosed in Scheme 21 (page 31, 32) and Example 3 of WO 99/02514 (pages 48 - 50). The transformation of a compound of formula I which is different from epothilone B into the corresponding lactam can be accomplished analogously. Corresponding epothilone derivatives of formula I wherein R_N is lower alkyl can be prepared by methods known in the art such as a reductive alkylation reaction starting from the epothilone derivative wherein R_N is hydrogen.

It will be understood that in the discussion of methods, references to the active ingredients are meant to also include the pharmaceutically acceptable salts. If these active ingredients have, for example, at least one basic center, they can form acid addition salts. Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center. The active ingredients having an acid group (for example COOH) can also form salts with bases. The active ingredient or a pharmaceutically acceptable salt thereof may also be used in form of a hydrate or include other solvents used for crystallization.

In one preferred embodiment of the invention, an epothilone derivative of formula I is employed wherein A represents O, R is lower alkyl, especially methyl, ethyl or n-propyl, or hydrogen, R' is methyl and Z is O or a bond. More preferably, an epothilone derivative of formula I is employed wherein A represents O, R is methyl, R' is methyl and Z is O, which compound is also known as epothilone B.

The term "treatment" as used herein comprises the treatment of patients having myeloma or being in a pre-stage of said disease which effects the delay of progression of the disease in said patients and aims preferably to effect a complete response to the treatment, a partial response to the treatment or to effect a stable disease.

The term "complete response" as used herein means in particular to the resolution of all measurable or evaluable disease.

The term "partial response" as used herein means in particular a greater than or equal to 50 % reduction in measurable or evaluable disease in the absence of progression in any particular disease site.

The term "stable disease" as used herein means in particular a less than 50 % decrease or less than 25 % increase in measurable or evaluable disease.

The present invention pertains also to a combination comprising (a) an epothilone and (b) at least one compound selected from the group consisting of alkylating agents, corticosteroids and anthracyclines. in particular, for the simultaneous, separate or sequential use in the treatment of myeloma.

The term "alkylating agent" as used herein includes, but is not limited to, alkyl sulfonates, aziridines, epoxides, ethylenimines, methylmelamines, nitrogen mustards, nitrosoureas, imidazotetrazinones, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman and procarbazine.

The term "alkyl sulfonates" as used herein includes, but is not limited to, busulfan, improsulfan and piposulfan.

The term "aziridines" as used herein includes, but is not limited to, benzodepa, carboquone, meturedpa and uredepa.

The term "ethylenimines and methylmelamines" as used herein includes, but is not limited to, altretamine, triethylenemelamine, triethylenephosphoramidate, triethylenethiophosphoramidate and trimethylolmelamine.

The term "nitrogen mustards" as used herein includes, but is not limited to, chlorambucil, chlornaphazine, cyclophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide and uracil mustard.

The term "nitrosoureas" as used herein includes, but is not limited to, carmustine, chlorozotocin, cytemustine, fotemustine, lomustine (CCNU), nimustine and ranimustine.

The term "imidazotetrazinones" as used herein includes, but is not limited to, temozolomide and mitozolomide.

"Temozolomide" is described in US 5,260,291. The synthesis of temozolomide is well known e.g., Wang *et al.*, J. Org. Chem. 1997, 62, 7288-7294). Temozolomide is commercially available e.g. under the trademark of TEMODAL™, TEMODAR™, or TEMOXOL™ and can be administered, e.g., as described in US 5,942,247 or according to the package insert information. The term "lomustine" means a compound as described and prepared e.g. in Johnson P *et al.*, J. Med. Chem. 1966, 9, 892. Lomustine is commercially available under the trademark BETULUSTINE™ and can be administered according to the package insert information.

The term "anthracyclines" as used herein includes, but is not limited to, doxorubicine and daunorubicine.

Furthermore, the structure of the active agents mentioned herein by name may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g. Patents International (e.g. IMS World Publications). The corresponding content thereof is hereby incorporated by reference. Any person skilled in the art is fully enabled, based on these references, to manufacture and test the pharmaceutical indications and properties in standard test models, both *in vitro* and *in vivo*.

A combination comprising (a) an epothilone and (b) at least one compound selected from the group consisting of alkylating agents, corticosteroids and anthracyclines, in which the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier, will be referred to hereinafter as a COMBINATION OF THE INVENTION.

The COMBINATION OF THE INVENTION can be a combined preparation or a pharmaceutical composition.

The term "a combined preparation", as used herein defines especially a "kit of parts" in the sense that the active ingredients as defined above can be dosed independently or by use of different fixed combinations with distinguished amounts of the ingredients, i.e., simultaneously or at different time points. The parts of the kit can then, e.g., be administered simultaneously or chronologically staggered, that is at different time points and with equal or different time intervals for any part of the kit of parts. Very preferably, the time intervals are chosen such that the effect on the treated disease in the combined use of the parts is larger than the effect which would be obtained by use of only any one of the active ingredients. The ratio of the total amounts of the active ingredient 1 to the active ingredient 2 to be administered in the combined preparation can be varied, e.g., in order to cope with the needs of a patient sub-population to be treated or the needs of the single patient which different needs can be due to age, sex, body weight, etc. of the patients. Preferably, there is at least one beneficial effect, e.g., a mutual enhancing of the effect of the first and second active ingredient, in particular a synergism, e.g. a more than additive effect, additional advan-

tageous effects, less side effects, a combined therapeutical effect in a non-effective dosage of one or both of the first and second active ingredient, and especially a strong synergism the first and second active ingredient.

Additionally, the present invention provides a method of treating myeloma comprising administering a COMBINATION OF THE INVENTION in an amount which is jointly therapeutically effective against myeloma to a warm-blooded animal in need thereof.

The person skilled in the pertinent art is fully enabled to select relevant test models to prove the hereinbefore and hereinafter mentioned beneficial effects on myeloma of an epothilone or of a COMBINATION OF THE INVENTION. The pharmacological activity of an epothilone or a COMBINATION OF THE INVENTION may, for example, be demonstrated in a suitable clinical study or by means of the Examples described below. By the methods described below it can be shown, e.g., that epothilone B inhibits the growth and survival of MM cells with an IC₉₀ between 1 and 10 nM. Epothilone B induces G2M arrest in MM cells with subsequent apoptosis. Suitable clinical studies are, for example, open label non-randomized, dose escalation studies in patients with advanced myeloma. Such studies prove in particular the synergism observed with the COMBINATIONS OF THE INVENTION. The beneficial effects on myeloma can be determined directly through the results of such studies or by changes in the study design which are known as such to a person skilled in the art. For example, one combination partner can be administered with a fixed dose and the dose of a second combination partner is escalated until the Maximum Tolerated Dosage (MTD) is reached. Alternatively, a placebo-controlled, double blind study can be conducted in order to prove the benefits of the COMBINATION OF THE INVENTION mentioned herein.

It is one objective of this invention to provide a pharmaceutical composition comprising a quantity, which is jointly therapeutically effective against myeloma comprising the COMBINATION OF THE INVENTION. In this composition, the combination partners can be administered together, one after the other or separately in one combined unit dosage form or in two separate unit dosage forms. The unit dosage form may also be a fixed combination.

The pharmaceutical compositions for separate administration of the combination partners and for the administration in a fixed combination, i.e. a single galenical composition comprising at least two combination partners, according to the invention can be prepared in

a manner known per se and are those suitable for enteral, such as oral or rectal, and parenteral administration to mammals (warm-blooded animals), including man, comprising a therapeutically effective amount of at least one pharmacologically active combination partner alone or in combination with one or more pharmaceutically acceptable carries, especially suitable for enteral or parenteral application.

Novel pharmaceutical composition contain, for example, from about 10 % to about 100 %, preferably from about 20 % to about 60 %, of the active ingredients. Pharmaceutical preparations for the combination therapy for enteral or parenteral administration are, for example, those in unit dosage forms, such as sugar-coated tablets, tablets, capsules or suppositories, and furthermore ampoules. If not indicated otherwise, these are prepared in a manner known per se, for example by means of conventional mixing, granulating, sugar-coating, dissolving or lyophilizing processes. It will be appreciated that the unit content of a combination partner contained in an individual dose of each dosage form need not in itself constitute an effective amount since the necessary effective amount can be reached by administration of a plurality of dosage units.

In particular, a therapeutically effective amount of each of the combination partner of the COMBINATION OF THE INVENTION may be administered simultaneously or sequentially and in any order, and the components may be administered separately or as a fixed combination. For example, the method of treatment of myeloma according to the present invention may comprise (i) administration of a combination partner (a) in free or pharmaceutically acceptable salt form and (ii) administration of a combination partner (b) in free or pharmaceutically acceptable salt form, simultaneously or sequentially in any order, in jointly therapeutically effective amounts, preferably in synergistically effective amounts, e.g. in daily dosages corresponding to the amounts described herein. The individual combination partners of the COMBINATION OF THE INVENTION can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms. Furthermore, the term administering also encompasses the use of a pro-drug of a combination partner that convert *in vivo* to the combination partner as such. The instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term "administering" is to be interpreted accordingly.

The effective dosage of the epothilones and of the combination partners employed in the COMBINATION OF THE INVENTION may vary depending on the particular compound or pharmaceutical composition employed, the mode of administration, the type of the myeloma being treated and the severity of the myeloma being treated. Thus, the dosage regimen the COMBINATION OF THE INVENTION is selected in accordance with a variety of factors including the route of administration and the renal and hepatic function of the patient. A physician, clinician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of an epothilone or of the single active ingredients of the COMBINATION OF THE INVENTION required to prevent, counter or arrest the progress of the condition. Optimal precision in achieving concentration of the active ingredients within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the active ingredients' availability to target sites.

When the combination partners employed in the COMBINATION OF THE INVENTION are applied in the form as marketed as single drugs, their dosage and mode of administration can take place in accordance with the information provided on the package insert of the respective marketed drug in order to result in the beneficial effect described herein, if not mentioned herein otherwise.

If the the warm-blooded animal is a human, the dosage of a compound of formula I is preferably in the range of about 0.1 to 75, preferably 0.25 to 50, e.g. 2.5 or 6, mg/m² once weekly for two to four, e.g. three, weeks, followed by 6 to 8 days off in the case of an adult patient.

In one embodiment of the invention, epothilone B is administered weekly in a dose that is between about 0.1 to 6 mg/m², preferably between 0.1 and 3 mg/m², e.g. 2.5 mg/m², for three weeks after an interval of one to six weeks, especially an interval of one week, after the preceding treatment. In another embodiment of the invention said epothilone B is preferably administered to a human every 18 to 24 days in a dose that is between about 0.5 and 7.5 mg/m².

Temozolomide is preferably administered daily at a dose of 50 to 300 mg/m²/day, most preferably 200 mg/m²/day in cycles of 5 consecutive days per 28 day cycle. For patients who had prior chemotherapy, treatment is generally started at 150 mg/m²/day.

Lomustine is preferably administered at a single dose of 60 to 180 mg/m² once every six weeks preferably at a dose of 130 mg/m².

Moreover, the present invention provides a commercial package comprising as active ingredients the COMBINATION OF THE INVENTION, together with instructions for simultaneous, separate or sequential use thereof in the treatment of myeloma.

The present invention also provides the use of a compound of formula I as defined herein and the use of a COMBINATION OF THE INVENTION for the preparation of a medicament for the treatment of myeloma.

Examples

General

RPMI 8226 and U266 human MM cell lines can be obtained from the American Type Culture Collection (ATCC) of Rockville, MD. Patient derived MM cells are purified from patient BM samples, as described by Y.T. Tai, G. Teoh, Y. Shima, et al in J. Immunol. Methods 235:11, 2000. All human MM cell lines are cultured in RPMI-1640 media (Sigma Chemical, St. Louis, MO), containing 10% fetal bovine serum (FBS), 2mmol/L L-glutamine (L-glut, GIBCO, Grand Island, NY), 100U/mL penicillin and 100mg/mL streptomycin (P/S, GIBCO). MM patient cells are $\geq 95\%$ CD38+, CD45RA-. Bone marrow stromal cells (BMSCs) are prepared from aspirates of MM patients as well as healthy donors as described by D. Gupta, S. Treon, Y. Shima, et al in Leukemia, 2001 and S. Gartner and H.S. Kaplan in Proc. Natl. Acad. Sci. U S A 77:4756, 1980. Cells are cultured in ISCOVE's modified Dulbecco media containing 20% FBS, 2mmol/L L-glut, and 100ug/mL P/S. Human umbilical vein endothelial cells (HUVEC P168) are purchased from Clonetics, Biowhittaker, and maintained in EGM-2MV media (Clonetics, Biowhittaker). The epothilones are dissolved in dimethyl sulfoxide (DMSO; Sigma) and stored as a stock solution at -20°C until used. For all assays, the compound is diluted in culture medium to concentrations ranging, e.g., from 0.01 to 100µM.

Cytokine levels are measured in supernatants from the co-culture system described above. VEGF and IL-6 concentrations are measured using commercially available ELISA kits (R&D Systems).

Cell Protein Lysates, Immunoprecipitation and Western Blot Analysis

MM cells are starved for 12h in RPMI with 10% FBS, and then incubated for 1h in RPMI-1640 without FBS in the presence of an epothilone or DMSO control. These cells are subsequently stimulated with 100nM VEGF₁₆₅ as described by K. Podar, Y.T. Tai, et al in Blood 98:428, 2001. Cells are then lysed in RIPA buffer containing 1mM PMSF, 1mM Sodium vanadate, and a protease inhibitor cocktail (Boehringer Mannheim). Lysates are either analyzed directly on a sodium dodecyl sulfate –polyacrylamide gel (SDS-PAGE gel) or incubated overnight with an antibody (Ab) against Flt-1, as well as protein G plus-Agarose (both from Santa Cruz Biotechnology, CA). Whole cell lysates (30µg per lane) or immunoprecipitates are analyzed on an 8 to 10% SDS-PAGE gel; transferred onto Hybond C Super paper (Amersham, Arlington Heights, IL); then probed with a murine MoAb against phospho-ERK, a murine MoAb against phospho-tyrosine residues, or Abs against Flt-1 or ERK2 (Santa Cruz); and detected using an HRP-conjugate anti-murine or anti-rabbit Ab (both from Santa Cruz) and enhanced chemiluminescence (ECL) substrate solution (Amersham).

Western Blotting

Protein lysates from drug-treated and control MM cells are prepared using RIPA buffer in the presence of a protease inhibitor cocktail (Roche), 1mM PMSF, and 1mM sodium orthovanadate. Lysates are either analyzed directly on sodium dodecyl sulfate – polyacrylamide (SDS-PAGE) gel; transferred onto Hybond C Super paper (Amersham, Arlington Heights, IL); probed with a murine MoAb against bcl-2 (Santa Cruz, Santa Cruz, CA), bax (Santa Cruz), or PARP (Biomol, West Grove, PA), or rabbit polyclonal Ab against caspase 3 (Santa Cruz), as well as goat polyclonal Ab against actin, and detected using an HRP-conjugated anti-murine or anti- goat Ab (both from Santa Cruz) and enhanced chemiluminescence (ECL) substrate solution (Amersham).

Proliferation and Cell Viability Assays

MM cells are first starved for 12h in RPMI-1640 media containing 10% fetal bovine serum, and then plated into 96-well microtiter plates (Costar, Cambridge, MA), in the presence of drug or DMSO control. Experiments are also performed in the presence or absence of VEGF₁₆₅ (R and D Systems). Proliferation is measured by the incorporation of [³H]-thymidine (NEN Products, Boston, MA). Specifically, cells are pulsed with [³H]-thymidine (0.5 µCi/well) for the last 6h of 48h cultures, harvested onto glass filters with an automatic cell harvester (Cambridge Technology, Cambridge, MA), and counted using a LKB Betaplate scintillation counter (Wallac, Gaithersburg, MD). Measurement of cell viability is performed colorimetrically by MTS assay, utilizing the CellTiter96 AQueous One Solution Reagent (Promega, Madison, WI). Cells are exposed to the MTS for the last 2 h of 48h cultures, and absorbance is measured using an ELISA plate reader (Molecular Devices Corp., Sunnyvale, CA) at OD of 570 nm.

Cell Cycle Analysis

MM cells (1x10⁶ cells) are cultured in the presence of Epothilone B or DMSO control for 24, 48 and 72h. Cells are then washed with phosphate buffered saline (PBS), fixed with 70% ethanol, and treated with RNase (Sigma). Cells are next stained with propidium iodide (PI, 5µg/mL), and the cell cycle profile is determined using the M software on an Epics flow cytometer (Coulter Immunology, Hialeah, FL).

Example 1: Proliferation of MM Cells in an Adhesion System

BMSCs (1x 10⁴ cells/well) are plated into 96-well microtiter plates and incubated at 37°C for 24h in ISCOVE's media (20% FBS). MM cells are then added to the BMSC-containing wells (5 x 10⁴ cells/well), in the presence of an epothilone or DMSO control. When MM.1S cells are used, both BMSCs and MM cells are starved for 12h in RPMI-1640 media containing 2% FBS. When patient PCL cells are used, the co-cultures are performed in RPMI media containing 10% FBS. BMSCs and MM cells are also cultured separately to serve as controls. After 48h, proliferation and cell viability are analyzed as described above. To ensure that all cells are collected for the proliferation assay, 10x Trypsin (Sigma) is added to each well 10 minutes prior to harvesting.

Example 2: Proliferation of MM Cells in a modified Boyden Chamber Transwell System

Proliferation is measured in a modified Boyden chamber transwell system, using 24-well plates with a 0.4 mm pore size inserts (Costar). BMSCs (4×10^4 cells/well) are plated in the lower chamber, starved, and incubated in an epothilone as described above. MM cells (20×10^4 cells/ml) are then placed in the upper chamber (insert), and [^3H]-thymidine uptake in the individual chambers is measured at 48h as described above.

Example 3: Measurement of Cytokine Concentrations

Cytokine levels were measured in supernatants from the co-culture system described above. VEGF and IL-6 concentrations were measured using commercially available ELISA kits (R&D Systems).

Example 4: Effect of Epothilone B on Proliferation MM.1S Cells

MM.1S cells are placed in the upper chamber of a transwell co-culture system in order to preclude direct contact between MM cells and BMSCs, but nonetheless allow for diffusion of humoral factors. Despite the lack of contact between the two cell types, uptake of [^3H]-dT by MM.1S cells incubated with BMSCs is increased by 2.2-fold ($p < 0.0001$) at 48h. By contrast, the BMSCs in the co-culture system do not show a significant increase in [^3H]-dT uptake. It can be shown by this co-culture system that epothilone B reduces proliferation of MM.1S cells.


Example 5: Effect of Epothilone B on human MM cells *in vivo*

Mice are inoculated subcutaneously into the right flank with 3×10^7 MM cells in 100 mL of RPMI 1640, together with 100 uL matrigel basement membrane matrix (Becton Dickinson, Bedford, MA). On day 6 post injection, mice are assigned into two treatment groups receiving Epothilone B, or into a control group. Treatment with Epothilone B is given intravenously once weekly via tail vein at 2.5 mg/kg for 4 weeks, starting on day +6, or as a one-time 4mg/kg dose on day +6. The control group receive the vehicle alone (30% PEG-300 in 0.9% sodium chloride) weekly. Caliper measurements of the longest perpendicular tumor diameters are performed twice per week to estimate the tumor volume, using the following formula: $\frac{4}{3} \times (\text{width}/2)^2 \times (\text{length}/2)$, representing the three-dimensional volume

of an ellipse. Animals are sacrificed when their tumor reached 2 cm or when the mice become moribund. Survival is evaluated from the first day of tumor injection until death.

What is claimed


1. A method of treating a warm-blooded animal having myeloma comprising administering a therapeutically effective amount of an epothilone.
2. The method of claim 1 wherein the epothilone is a compound of formula I



wherein A represents O or NR_N, wherein R_N is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino or methylthio, and Z is O or a bond,
or a pharmaceutically acceptable salt thereof to a warm-blooded animal in need thereof.

3. The method according to claim 1 or 2 wherein the warm-blooded animal is a human.
4. A method according to anyone of claims 1 to 3 wherein the myeloma is resistant to conventional cytotoxic chemotherapy.
5. A method according to anyone of claims 1 to 3 wherein overexpression of the multi-drug resistance protein p170 is observed.
6. A method according to anyone of claims 1 to 3 wherein the myeloma is resistant to a taxane, e.g., paclitaxel.
7. The method according to anyone of claims 1 to 6 wherein the disease is multiple myeloma.

8. The method according to anyone of claims 1 to 7 wherein the compound of formula I is epothilone B.
9. The method according to 8 comprising administering epothilone B weekly in a dose that is between about 0.1 to 6 mg/m² for three weeks after an interval of one to six weeks after the preceding treatment.
10. A combination comprising (a) an epothilone of formula I



wherein A represents O or NR_N, wherein R_N is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino or methylthio, and Z is O or a bond, and (b) at least one compound selected from the group consisting of alkylating agents, corticosteroids and anthracyclines, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential use in the treatment of myeloma.

11. Combination according to claim 10 wherein the epothilone is epothilone B.
12. Combination according to claim 11 or 12 for simultaneous, separate or sequential use in the treatment of multiple myeloma.
13. Use of a combination according to claim 11 or 12 for the preparation of a medicament for the treatment of myeloma.

14. A method of treating myeloma comprising administering a combination as defined in claim 11 in an amount which is jointly therapeutically effective against myeloma to a warm-blooded animal in need thereof.
15. A pharmaceutical composition comprising a quantity, which is jointly therapeutically effective against myeloma, of a combination according to claim 11 and at least one pharmaceutically acceptable carrier.
16. A commercial package comprising a combination as defined in claim 11, together with instructions for simultaneous, separate or sequential use thereof in the treatment of myeloma.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 03/04480

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/427 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 03 022844 A (SLOAN KETTERING INST CANCER ;LEE CHULBOM (US); RIVKIN ALEXEY (US);) 20 March 2003 (2003-03-20) claims 1-19 page 79, line 14 -page 80, line 25 page 83, line 27 ---	1,3-7
X	WO 99 02514 A (SQUIBB BRISTOL MYERS CO) 21 January 1999 (1999-01-21) cited in the application claims 1-5 page 8, line 31 - line 32 page 10, line 10 -page 11, line 12 ---	1-16
X	US 2002/058286 A1 (WU ZHICAI ET AL) 16 May 2002 (2002-05-16) claims 1-35 column 32, line 332 -column 33, line 335 ---	1-16
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

A document member of the same patent family

Date of the actual completion of the international search

5 December 2003

Date of mailing of the international search report

17/12/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Siatou, E

INTERNATIONAL SEARCH REPORT

International Application No

PCT/10 03/04480

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 399 638 B1 (HOEFLE GERHARD ET AL) 4 June 2002 (2002-06-04) claims 1-7	1,3-7
Y	page 6, line 57, paragraph 332 -page 7, line 18, paragraph 334 ---	2,8,9, 13,14
X	WO 99 43320 A (NOVARTIS ERFIND VERWALT GMBH ;NOVARTIS AG (CH)) 2 September 1999 (1999-09-02)	10-12, 15,16
Y	page 9, last paragraph -page 11, line 7 page 17, line 1 -page 18, line 6 page 23, line 4 - line 11 ---	2,8,9, 13,14
X	WO 01 64650 A (SLOAN KETTERING INST CANCER ;CHAPPELL MARK (US); STACHEL SHAWN (US) 7 September 2001 (2001-09-07) claims 1-63 page 12, line 4 - line 21 page 77, line 29 page 78, line 5 - line 28 ---	1,3-7
X	WO 01 10412 A (NOVARTIS ERFIND VERWALT GMBH ;NOVARTIS AG (CH); WARTMANN MARKUS (C) 15 February 2001 (2001-02-15) page 1, line 6 - line 24 page 8, line 12 -page 9, line 21 ---	10-12
A	ALTMANN K-H ET AL: "Epothilones and related structures - a new class of microtubule inhibitors with potent in vivo antitumor activity" BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1470, no. 3, 17 May 2000 (2000-05-17), pages M79-M91, XP004281887 ISSN: 0304-419X the whole document ---	1-16
A	LEE F Y F ET AL: "BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy" CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 7, no. 5, May 2001 (2001-05), pages 1429-1437, XP002254263 ISSN: 1078-0432 the whole document -----	1-16

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB 03/04480

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-9 and 14 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IL 03/04480

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03022844	A	20-03-2003	WO 03022844 A2 US 2003176368 A1	20-03-2003 18-09-2003
WO 9902514	A	21-01-1999	AU 731497 B2 AU 7972098 A BG 104068 A BR 9810555 A CN 1270589 T EE 200000013 A EP 1019389 A2 HU 0103111 A2 JP 2002512634 T LT 99153 A , B LV 12569 A LV 12569 B NO 20000076 A NZ 501198 A PL 338003 A1 SK 181799 A3 TR 200000065 T2 US 6605599 B1 WO 9902514 A2 ZA 9805938 A	29-03-2001 08-02-1999 29-09-2000 15-08-2000 18-10-2000 15-08-2000 19-07-2000 29-04-2002 23-04-2002 25-08-2000 20-11-2000 20-04-2001 07-01-2000 28-09-2001 25-09-2000 06-08-2001 21-11-2000 12-08-2003 21-01-1999 10-01-2000
US 2002058286	A1	16-05-2002	US 6204388 B1 US 2003105330 A1 US 2003069277 A1 US 2003208080 A1 US 6316630 B1	20-03-2001 05-06-2003 10-04-2003 06-11-2003 13-11-2001
US 6399638	B1	04-06-2002	AU 757733 B2 AU 3382799 A AU 748526 B2 AU 3471699 A BR 9909795 A CA 2323609 A1 CA 2329181 A1 CN 1298398 T EP 1073647 A1 EP 1073648 A1 JP 2002512238 T JP 2002512239 T TR 200003036 T2 WO 9954318 A1 WO 9954319 A1 US 6380395 B1	06-03-2003 08-11-1999 06-06-2002 08-11-1999 26-12-2000 28-10-1999 28-10-1999 06-06-2001 07-02-2001 07-02-2001 23-04-2002 23-04-2002 22-01-2001 28-10-1999 28-10-1999 30-04-2002
WO 9943320	A	02-09-1999	AU 755944 B2 AU 2927999 A BE 1011980 A5 CA 2319752 A1 WO 9943320 A1 EP 1056453 A1 FR 2775187 A1 IT MI990375 A1 JP 2002504511 T NZ 506187 A US 6302838 B1	02-01-2003 15-09-1999 07-03-2000 02-09-1999 02-09-1999 06-12-2000 27-08-1999 25-08-1999 12-02-2002 28-11-2003 16-10-2001

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB03/04480

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9943320 A		US 2002028839 A1	07-03-2002
WO 0164650 A	07-09-2001	AU 4337201 A	12-09-2001
		CA 2401800 A1	07-09-2001
		EP 1259490 A2	27-11-2002
		WO 0164650 A2	07-09-2001
		US 2002058817 A1	16-05-2002
WO 0110412 A	15-02-2001	AU 6279500 A	05-03-2001
		WO 0110412 A1	15-02-2001
		EP 1198225 A1	24-04-2002

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.